DIS® Platform

Breakthrough BioTech AI Innovation of the Year!

Enhancing Success from Target to Patient
Our unique Drug Intelligence Science (DIS®) platform combines a cutting-edge single-cell instrument with AI based data analysis to maximize the probability of success throughout the drug discovery and development process.

DIS® powered data analysis and novel droplet-based target discovery allows us to harness the power of machine learning to obtain biologically relevant insights at the single-cell level.  AI and machine learning enable unprecedented cross-dataset analysis in the single-cell space and empower us to discover novel targets with strong translatability into curative therapies.

DIS® powered antibody discovery allows for the screening of millions of species agnostic B cells within hours (CelliGo™) and analysis with proprietary single-cell bioinformatics (AbSolution™). Our machine learning model guides antibody binding prediction and affinity maturation.  

DIS® powered single-cell profiling of patient samples together with AI and machine learning, we can identify indications where our therapeutics can achieve immune modulation and discover predictive biomarkers for patient treatment response, ultimately leading to an increase in the success rates of treatments.

Enhancing Success from Target to Patient
Our unique Drug Intelligence Science (DIS®) platform combines a cutting-edge single-cell instrument with AI based data analysis to maximize the probability of success throughout the drug discovery and development process.

DIS® powered data analysis and novel droplet-based target discovery allows us to harness the power of machine learning to obtain biologically relevant insights at the single-cell level.  AI and machine learning enable unprecedented cross-dataset analysis in the single-cell space and empower us to discover novel targets with strong translatability into curative therapies.

DIS® powered antibody discovery allows for the screening of millions of species agnostic B cells within hours (CelliGo™) and analysis with proprietary single-cell bioinformatics (AbSolution™). Our machine learning model guides antibody binding prediction and affinity maturation.  

DIS® powered single-cell profiling of patient samples together with AI and machine learning, we can identify indications where our therapeutics can achieve immune modulation and discover predictive biomarkers for patient treatment response, ultimately leading to an increase in the success rates of treatments.

Innovative and Versatile Single Cell Instrument

5-10K Drops/sec

10+ Assay Formats

3-9 Month Hit to Candidate

Our proprietary microfluidic instrument enables high-throughput single-cell analysis, including functional screening, sorting, and multi-omic immune cell profiling. Individual cells are encapsulated in picoliter droplets. Droplets act as independent reactors that are generated and analyzed at thousands of droplets per second.

Publications and Presentations

American Association for Cancer Research | Poster | April 9, 2024

Integrating public single-cell transcriptomics and patient profiles to guide clinical developmentIntegrating public single-cell transcriptomics and patient profiles to guide clinical development

American Association for Cancer Research | Poster | April 08, 2022

Discovery of predictive biomarkers of response to T cell-targeting biologics using ex vivo single-cell profiling coupled with TCR clonotype characterizationDiscovery of predictive biomarkers of response to T cell-targeting biologics using ex vivo single-cell profiling coupled with TCR clonotype characterization

Science Advances | Publication | June 11, 2021

High-throughput functional screening for next-generation cancer immunotherapy using droplet-based microfluidicsHigh-throughput functional screening for next-generation cancer immunotherapy using droplet-based microfluidics

American Association for Cancer Research | Presentation | September 17, 2020

HiFiBiO Therapeutics Presents Novel Approach to Patient Stratification Demonstrating DIS™ Single-Cell Platform at 2020 AACR Tumor Heterogeneity Conference

Nature Biotechnology | Publication | March 30, 2020

High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidicsHigh-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics

Nature Genetics | Publication | May 31, 2019

High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancerHigh-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer

Nature Biotechnology | September 11, 2017

Single-cell deep phenotyping of IgG-secreting cells for high-resolution immune monitoringSingle-cell deep phenotyping of IgG-secreting cells for high-resolution immune monitoring

HiFiBio, Paris | Poster | November 13, 2016

Antibody Discovery by Deep Mining of Immune Repertoires: A demonstration of the HiFiBiO CelliGO™ Platform versatility and robustness with Tetanus Toxoid antigen as a case studyAntibody Discovery by Deep Mining of Immune Repertoires: A demonstration of the HiFiBiO CelliGO™ Platform versatility and robustness with Tetanus Toxoid antigen as a case study